Research articlePublished 30 May 2016

Docetaxel Based Treatment for Metastatic Castration-Resistant Prostate Cancer-our Early Experience

Authors: Shridhar C Ghagane, Rajendra B Nerli, Murigendra B Hiremath, Bassappa B Kaliwal

Translational Biomedicine

Volume 7 · Issue 2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: Patients with metastatic prostate cancer invariably progress after primary androgen ablation and develop castration-resistant disease after a median time of 18-24 months. We report our early experience with docetaxel based chemotherapy in patients with mCRPC. Methods: Patients with rising serum Prostate-specific antigen, increasing extent of disease on bone scans and physical findings. All eligible patients with no previous treatment with any cytotoxic drug and having a good ≥80 Karnofsky performance status were included into the study. Results: 85 patients with metastatic prostate cancer presented with progressive disease following ADT. 67 (78.82%) patients with a mean age of 67.05 ± 2.11 accepted further treatment with docetaxel based chemotherapy, whereas the remaining 18 (21.18%) patients with mean age of 68.0 ± 4.47 years did not undergo further treatment. The overall survival was 32.61 ± 6.09 months in patients receiving docetaxel based chemotherapy as compared to 12.83 ± 2.40 months in patients in the no treatment group. The Serum PSA values at 3 and 9 months after initiation of treatment showed a downward trend in all the three risk groups receiving docetaxel. Conclusions: In our study the overall survival was 32.61 ± 6.09 months in patients receiving docetaxel. Serum PSA decline rates at least 50% from baseline was seen in 34.32% of patients at 3 months on docetaxel treatment. Docetaxel was also effective in pain reduction, decline in serum PSA levels and improvement in health related quality of life. Our study demonstrates significant response rates to docetaxel chemotherapy but that a considerable number of patients had treatment-related complications. This highlights the need for careful patient selection and optimization of chemotherapy dosing.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Biomedicine
  • SubjectOncology & Cancer
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Shridhar C Ghagane”
  • BylineArticles whose byline prints “Rajendra B Nerli”
  • BylineArticles whose byline prints “Murigendra B Hiremath”
  • BylineArticles whose byline prints “Bassappa B Kaliwal”